TATA Health International Holdings Limited
TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

EXPIRY OF THE LONG STOP DATE OF DISCLOSEABLE TRANSACTION

References are made to the announcements of TATA Health International Holdings Limited (the "**Company**") dated 29 June 2021 (the "**First Announcement**"), 10 August 2021, 30 August 2021, and 20 October 2021 in relation to, among other things, the Investment. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the First Announcement.

As the conditions precedent to the Investment and Shareholders Agreement and the Share Purchase Agreement have not been fulfilled and/or waived (as the case maybe) by the Long Stop Date, the Investment and Shareholders Agreement and the Share Purchase Agreement have lapsed. As a definitive Sub-License Agreement has not been signed by the Long Stop Date, the Sub-License Agreement Term Sheet has automatically terminated. The Investment will not proceed.

Shang Ying has paid a sum of EUR500,000 to date, being cash advance under the Investment and Shareholders Agreement. Shang Ying has not paid the EUR1,000,000 additional cash advance under the amendment agreement to the Investment and Shareholders Agreement dated 30 August 2021. The Company is seeking legal advice as to next steps.

By order of the Board
TATA Health International Holdings Limited
Yang Jun
Chairman

Hong Kong, 27 October 2021

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Yang Jun and Mr. Lai Wenjing; four non-executive Directors, namely, Mr. Lin Zheming, Mr. Lin Jun, Mr. Chu Chun Ho, Dominic and Mr. Chen Anhua and three independent non-executive Directors, namely, Mr. Xie Rongxing, Prof. Yan Haifeng and Ms. Tan Yuying.